
The rising use in the US of so-called GLP-1 drugs to suppress appetite and, as a consequence, lose weight, is causing some concern among investors in food and drinks companies, including in beverage alcohol groups.
The number of monthly doses being administered in the US of drugs like Ozempic “are now at around 11m and rising”, AllianceBernstein says.
The rising use in the US of so-called GLP-1 drugs to suppress appetite and, as a consequence, lose weight, is causing some concern among investors in food and drinks companies, including in beverage alcohol groups.